AMG0103
Phase 1Small molecule
AMG0103 is one of 43 small molecule programs targeting Back pain. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
87 competitors in Back Pain
#DrugCompanyPhaseTrials
1Lexapro
AbbVieApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Buprenorphine/naloxone
AstellasApproved
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Suboxone
IIndivior Inc.
Phase 3
Botox
AbbViePhase 3
Buprenorphine IV
PPurdue Pharma LP
Phase 3
Pelubiprofen
Daewon Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMG0103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAnGes, Inc.